Feature | Stents Peripheral | November 06, 2019 | Dave Fornell, Editor

No Increased Long-Term Mortality for the Paclitaxel-Coated Zilver PTX Stent

No increased death caused by drug-coated stent compared to uncoated devices in VIVA 2019 late-breaker

The final, long-term, patient-level data for the Cook Medical Zilver PTX drug-eluting stent (DES) were evaluated to determine if there is an increased mortality risk due to paclitaxel, but was no difference was seen in the five-year mortality rates compared to control patients. #VIVA19 #VIVA #VIVA2019

The final, long-term, patient-level data for the Cook Medical Zilver PTX drug-eluting stent (DES) were evaluated to determine if there is an increased mortality risk due to paclitaxel, but was no difference was seen in the five-year mortality rates compared to control patients.

 


November 6, 2019 – The final, long-term, patient-level data for the Cook Medical Zilver PTX drug-eluting stent (DES) were evaluated to determine if there is an increased mortality risk due to paclitaxel and the results were presented at the 2019 Vascular Interventional Advances (VIVA) meeting. There was no difference in the five-year mortality rates between paclitaxel device treated patients and controls groups, reported Michael D. Dake, M.D., senior vice president for health sciences at the University of Arizona. 

The safety of paclitaxel-coated devices, and specifically the Silver, were raised in a meta-analysis published in Journal of the American Heart Association in December 2018. That analysis showed a higher mortality rate at two years post-procedure and prompted the U.S. Food and Drug Administration (FDA) to release a warning letter on the subject in 2019. This late-breaking data presented at VIVA 2019 was assembled to determine if there is a true safety signal or if the data findings were an anomaly.

Read the article 

Because risk factors common in patients with peripheral artery disease (PAD) may collectively contribute to patient prognosis, the contribution of baseline patient risk factors to mortality and freedom from target lesion revascularization (TLR) were also investigated in the Zilver PTX data. Some experts point to the fact that there is no smoking gun showing any single cause of paclitaxel causing high mortality rates. This led some experts to speculate that the patients involved in the trials may simply have higher mortality risk factors and that might be the cause of deaths.

Mortality through five years was compared for the primary randomization groups, which included 40% DES patients in the control group, as well as for the actual treatment groups. Actual treatment analysis compared patients treated with the DES to patients treated with nonpaclitaxel therapies. Imbalances in patient risk factors were considered. Mortality and freedom from TLR were evaluated for DES and percutaneous transluminal angioplasty (PTA)/bare-metal stent (BMS) risk factor groups.

Final five-year mortality data were available for 94% of patients. The intent-to-treat mortality analysis comparing the DES primary randomization group to the PTA primary randomization group was not significant (P = 0.08). Despite randomization, combinations of risk factors were more prevalent in the DES primary randomization group compared to the PTA primary randomization group (P < 0.01); the numeric difference in mortality rates between groups may be due to the imbalance of risk factors at baseline. When stratified by number of risk factors, patients with fewer risk factors had a decreased mortality rate.

When comparing actual treatment groups, there was no difference in the 5-year mortality rates for the DES group compared to the PTA/BMS group (19.1% vs 17.1%; P = .60). When evaluating potential risk factors for freedom from TLR, the DES showed benefit across the different risk factor groups; a greater relative benefit was observed in groups with fewer risk factors. Analyses of the Zilver PTX DES demonstrated no increase in long-term mortality and support a benefit across different risk factor groups.

The paclitaxel safety concern was a major topic of discussion at the FDA townhall meeting at the Transcatheter Cardiovascular Therapeutics (TCT) 2019 meeting in September. One TCT late-breaking study also showed there was no safety issue with the Lutonix 035 drug-coated balloon (DCB). Read more details in the article "LEVANT Trial Data Shows Safety of Drug-Coated Balloon at TCT 2019."

Find information on all the VIVA 2019 Late-breaking Clinical Trials

Related Paclitaxel Safety Issue Coverage:

Safety of Paclitaxel-eluting Stents and Balloons Called Into Question

6 Hot Topics in Interventional Cardiology at TCT 2019

FDA Panel Recommends Continued Use of Paclitaxel-coated Peripheral Devices

LEVANT Trial Data Shows Safety of Drug-Coated Balloon at TCT 2019
 


Related Content

News | Cardiovascular Clinical Studies

February 15, 2024 — Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and ...

Home February 15, 2024
Home
News | Cardiovascular Clinical Studies

January 3, 2024 — Cardionomic, Inc., a Minneapolis medical device company, is pleased to announce the completion of ...

Home January 03, 2024
Home
News | Cardiovascular Clinical Studies

December 19, 2023 — Peerbridge Health has announce the successful completion and findings of its prospective ...

Home December 19, 2023
Home
News | Cardiovascular Clinical Studies

December 14, 2023 — Published results of a large, national heart attack study show that patients with a life-threatening ...

Home December 14, 2023
Home
News | Cardiovascular Clinical Studies

December 11, 2023 — A world without cardiovascular disease (CVD) is possible, yet millions of lives are lost prematurely ...

Home December 11, 2023
Home
News | Cardiovascular Clinical Studies

December 8, 2023 — Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac ...

Home December 08, 2023
Home
News | Cardiovascular Clinical Studies

November 29, 2023 — Inari Medical, Inc., a medical device company with a mission to treat and transform the lives of ...

Home November 29, 2023
Home
News | Cardiovascular Clinical Studies

November 29, 2023 — Foldax, Inc., a leader in the development of innovative, polymer heart valves, today announced ...

Home November 29, 2023
Home
Subscribe Now